ERF:EURONEXT PARISEurofins Scientific SE Analysis

Eurofins Scientific (ERF) trades at €62.46, hovering just below its 20‑day SMA of €60.57 but still under the 50‑day SMA (€62.51) and well beneath the 200‑day SMA (€63.37), indicating a short‑term pullback within a longer‑term downtrend. Technical indicators are mixed: the RSI sits at a neutral 53.5, the MACD histogram is positive (0.39) with a bullish signal, yet the overall trend direction is flagged as bearish. Volatility remains elevated at 37.8% over the past 30 days, while a low beta of 0.38 suggests limited sensitivity to broader market moves. Fundamentally, the stock’s P/E of 24.5 is modestly below the industry average of 27.5, and the forward P/E of 13.4 points to improving earnings expectations. The dividend yield of 1.17% with a modest 23.5% payout ratio appears sustainable given free cash flow of €0.49 bn. Recent corporate actions, notably a share‑buyback programme targeting up to 4.5% of capital, provide a potential catalyst and align with analyst consensus (14 analysts rating a “buy”).
The DCF‑derived fair value of €23.9 suggests the market is pricing significant growth premium, yet analyst target prices around €70.6 imply an upside of roughly 13%, supporting a fair‑to‑undervalued view. Revenue growth of 4.3% and stable operating margins (13.3% operating, 6.5% net) underline a steady, if not high‑growth, business model. With a solid balance sheet, modest debt‑to‑equity of 96.8% (leveraged by cash reserves) and a dividend that can be comfortably covered, the company presents a resilient profile for patient investors.